Home >> ALL ISSUES >> 2020 Issues >> Cytopathology in focus: Abnormal cervical screening tests: a personal approach

Cytopathology in focus: Abnormal cervical screening tests: a personal approach

image_pdfCreate PDF

Barbara A. Crothers, DO
Diane Davis Davey, MD

August 2020—If the past decade was directed toward aligning medicine with a personalized approach to therapy, this decade should further realize the implementation of health care decisions tailored to the patient. The updated 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors take a large step in that direction by relying on the input of personal data into a free online application that provides suggested management planning based on patient history and prior Pap/HPV test results.1 The rapid changes in primary cervical cancer screening algorithms in the past decade have necessitated a reexamination of the thresholds for therapy and surveillance in the screened population. Current screening guidelines allow for primary HPV screening, cotesting using a Pap test and HPV testing, and Pap testing alone, depending on a woman’s age. This has resulted in a web of possible tests at variable intervals that may confound clinical decisions about appropriate follow-up.

As with the guidelines of 2001, 2006, and 2012, the 2019 consensus guidelines were developed by a consortium of professional organizations, including the CAP, patient advocacy groups, and the federal government, and were sponsored by the American Society for Colposcopy and Cervical Pathology with data and scientific support from the National Cancer Institute. Decisions were based on literature review and supportive evidence to the greatest extent possible. Where evidence was lacking or weak, consensus opinion provided a starting point. The preponderance of evidence was derived from prospective longitudinal data from 1.5 million Kaiser Permanente Northern California beneficiaries followed for more than a decade.2 The guiding decision-making principle was “equal management for equal risk” in recognition of every woman having a unique set of circumstances and tests that define her likelihood of developing cervical cancer. Other guiding principles are presented in Table 1.

A major change is the shift from complex algorithmic management flowcharts to a probabilistic model of management that relies on the estimated risk that a woman will develop cervical cancer using a surrogate endpoint of five-year risk of cervical intraepithelial neoplasia (CIN) grade 3 (CIN3) or a more severe lesion (CIN3+, Table 2. This probability model incorporates a woman’s clinical history of prior CIN and screening or follow-up HPV and Pap tests to produce a probable risk value, with colposcopy, treatment, or more frequent surveillance recommendations for those at highest risk. The probability model allows women at lower risk to extend screening intervals and should deter unnecessary colposcopy, biopsies, and cervical excision.

The probability application is sponsored by the National Cancer Institute and will be available to providers free via the internet. Providers will be able to enter the available clinical, screening, and biopsy data on their patients into their smartphones to identify a patient’s estimated risk and link it to an appropriate management recommendation. Examples of clinical information that might modify risk include HPV subtypes, past cytology and HPV screening history, treated squamous intraepithelial lesion (SIL) or cancer, and hysterectomy. The application (decision aid) will be updated as data become available on the efficacy of new triage tests (such as p16/Ki-67 dual staining or new tumor biomarkers) or virulence of specific HPV subtypes.

Decades of research have confirmed the higher sensitivity of HPV testing (compared with a single Pap test) to detect cervical cancer precursors, defined as cervical intraepithelial neoplasia grade 2 (CIN2), CIN3, and adenocarcinoma in situ (AIS). HPV tests have higher negative predictive value, while Pap tests add high specificity and will play a greater role in defining women at intermediate risk and in deferring women at low risk to surveillance. For example, a woman with a low-grade squamous intraepithelial lesion (LSIL) Pap test who was previously HPV negative or has a concurrent HPV-negative result can be followed with surveillance only, rather than receive colposcopy and biopsy confirmation. In the current guidelines, the term “HPV-based testing” is used to incorporate both primary HPV tests (HPV-only primary screening test) and cotests (HPV testing coupled with a Pap test, with or without HPV genotyping). The probability models incorporated into the decision application are affected by HPV subtype and duration of infection, reflecting current understanding of the pathogenesis of cervical cancer.

The guidelines are intended for high-resource settings where HPV testing, Pap tests, and colposcopy are readily available, and they should be applied to asymptomatic individuals with a cervix subject to cervical cancer screening. Women who present with clinical symptoms, such as vaginal bleeding, require different management strategies. The primary goal of cervical cancer screening and management is to detect and eradicate precursor lesions (CIN2,3/AIS) to prevent cervical cancer while weighing these benefits with the risk of under- or overtreatment. The ASCCP has published consensus colposcopy standards3 that emphasize the need to take multiple (two to four) targeted cervical biopsies in high-risk patients to detect precursor lesions, while additional untargeted biopsies provide little additional benefit in discovering lesions.

The guidelines establish five major action thresholds for clinical management: routine screening, one-year surveillance, three-year surveillance, colposcopy, and treatment.

Routine screening. Routine screening guidelines are not addressed by these recommendations and are determined under a separate process, but the current management guidelines assume women have initial (first-time) screening test results. Women ages 25 to 65 are candidates for primary HPV test screening (without a Pap test) at intervals of every five years. Cotesting (HPV test with a Pap test) may also be done every five years, but a Pap test alone every three years is also acceptable. These guidelines apply only to women who do not have HIV infection, DES exposure, an immunocompromised state, or cervical cancer. Women without a cervix (e.g. status post-hysterectomy) do not require screening if they have never had precancer or cancer.4 Individuals with negative screening tests remain in the “routine screening” population. Screening data constitute one of the minimal data points required for the decision aid.

Surveillance. Patient surveillance involves more intensive follow-up than recommended screening intervals and is based on the patient’s risk of developing cervical cancer. Individuals with a higher risk of CIN3+ than the general population, based on screening results and history, are prompted to return earlier for an office visit and HPV testing prior to the usual three- or five-year screening interval. This population harbors a risk of CIN3+ between the colposcopy threshold and a five-year screening interval. After review of evidence and data, the Surveillance Working Group retained the prior guideline intervals of one, three, and five years because the data supported cancer risk that aligned well with these intervals. The recommended follow-up test for surveillance is HPV-based testing (primary HPV test or cotest).

One-year surveillance. Individuals whose calculated risk (≥ 0.55 percent) is less than that of someone deferred for immediate colposcopy but greater than the three-year surveillance threshold are retested in one year.1 Individuals with a calculated risk below the threshold for immediate colposcopy (four percent) but above the three-year surveillance threshold (≥ 0.55 percent) are also in this category. Most of the following situations will result in a one-year surveillance recommendation:

  • Negative for intraepithelial lesion or malignancy (NILM)/HPV positive.
  • Two HPV-positive, Pap-negative results with colposcopy < CIN2.
  • Low-grade squamous intraepithelial lesion (LSIL)/HPV negative.
  • Histologic LSIL/CIN1 following HPV-positive atypical squamous cells-undetermined significance (ASC-US) or LSIL.
  • ASC-US/HPV positive following documented negative HPV test, cotest, or colposcopy.
  • LSIL following documented negative HPV test, cotest, or colposcopy.

Three-year surveillance. Individuals whose calculated risk (≥ 0.15 percent but < 0.55 percent) approximates that of an individual in the general screening population with a single negative Pap test are deferred for testing at three years. Most individuals with a colposcopy history of CIN1/LSIL and a current negative HPV test or cotest will fall into this window, as will those with an ASC-US screening Pap test that is HPV negative.

Five-year surveillance. Individuals with a calculated risk (< 0.15 percent) that approximates that of an individual in the general screening population following a single negative primary HPV test or cotest are deferred for testing at five years.

Colposcopy. Individuals with a calculated immediate risk (≥ four percent) of having CIN3+/AIS or cancer are referred to immediate colposcopy. This risk threshold was established using data on women with a CIN3+ diagnosis after immediate referral to colposcopy and not based on the overall long-term risk. The upshot of this recommendation is that most prior recommendations for direct referral to colposcopy still generally apply. For example, individuals with HSIL and atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) Pap tests are referred to colposcopy and should have targeted biopsies regardless of HPV results and prior history. Similarly, women with either ASC-US or LSIL/HPV+ cotests and previous unknown or HPV+ results should have colposcopy. Colposcopy is recommended for patients with either HPV18+ or HPV16+ results. Conversely, individuals with LSIL Pap tests or ASC-US/HPV+ cotests who would have been referred for colposcopy may now fall into one-year surveillance if they have had a prior documented negative HPV test, cotest, or colposcopy.

In pregnant women with CIN2, CIN3, or AIS, surveillance colposcopy every 12 to 24 weeks is preferred with treatment delayed until postpartum, and readers are referred to guidelines for details.

Treatment. For individuals age 25 and older with calculated immediate risk of CIN3+ ≥ 60 percent, an excisional procedure without prior colposcopy or biopsy confirmation is preferred, but colposcopy with biopsy is also acceptable. This risk is based on the person’s prior history and current screening results. For example, a 28-year-old woman with an HSIL Pap test that is HPV16+ would be scheduled for an excisional procedure. For those age 25 or older with a calculated risk between 25 and 59 percent, treatment without biopsy confirmation or following colposcopy and biopsies is acceptable. Examples are HSIL Pap test results, regardless of HPV status, and ASC-H/ HPV+ results.

Treatment is designed to eradicate precancerous tumor cells that have the potential to evolve into invasive cervical cancer. Progression rates of CIN3 to invasive squamous cell carcinoma cannot be studied effectively due to harm to the individual, but the only existing observational study indicated a progression of up to 30 percent over 30 years.5 As with previous guidelines, the threshold for excision is CIN2+/HSIL, except in special circumstances such as pregnancy.

Special clinical circumstances. Pregnancy and immunosuppression require modification of the guidelines. Pregnant women will follow the risk-based guidelines with the provisions for colposcopy and treatment described above.

Immunocompromised. Immunocompromised individuals include those with HIV and solid organ transplant, allogeneic hematopoietic stem cell transplant, systemic lupus erythematosus, inflammatory bowel disease, or rheumatologic disease requiring immunosuppressive therapy. These individuals have unique cervical cancer screening guidelines, beginning within one year of the onset of sexual activity and continuing throughout a person’s lifetime. Screening intervals are annually for three years, then every three years up to age 30 with Pap tests only, switching to cotesting every three years after age 30. Referral to colposcopy is recommended for any cotest result of ASC-US/HPV+ or worse. If the Pap test is ASC-US without HPV testing, then repeating the Pap test in six to 12 months is recommended, with colposcopy referral for any abnormal result. Colposcopy is recommended for any positive HPV test, and any LSIL, ASC-H, atypical glandular cells, and HSIL cytology regardless of the HPV result.

CAP TODAY
X